Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhao-Ru Dong

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Journal of Cancer|January 3, 2022
Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapiesYu-Chuan Yan, Guang-Xiao Meng, Zi-Niu Ding, et al.
Hepatology (Baltimore, Md.)|December 24, 2019
TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic CleavageZhao-Ru Dong, Dong Sun, Ya-Fei Yang, et al.
Frontiers in Immunology|February 25, 2022
The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-AnalysisCheng-Long Han, Guang-Xiao Meng, Zi-Niu Ding, et al.
Frontiers in Oncology|March 8, 2021
Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-AnalysisKai-Xuan Liu, Jian-Guo Hong, Rui Wu, et al.
Cell Death Discovery|March 7, 2025
Thyroid hormones inhibit tumor progression and enhance the antitumor activity of lenvatinib in hepatocellular carcinoma via reprogramming glucose metabolismChun-Cheng Yang, Yu-Chuan Yan, Guo-Qiang Pan, et al.
Expert Review of Gastroenterology & Hepatology|December 8, 2022
Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysisBao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, et al.
Expert Review of Gastroenterology & Hepatology|November 6, 2023
Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysisHan Li, Hui Liu, Lun-Jie Yan, et al.
International Immunopharmacology|December 7, 2023
Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohortsJun-Yu Long, Rui-Zhe Li, Dong-Xu Wang, et al.
Cell Death & Disease|August 25, 2025
Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinomaYu-Chuan Yan, Li-Juan Shao, Guang-Xiao Meng, et al.
Journal of Cancer Research and Clinical Oncology|February 11, 2025
Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysisShi-Jia Liu, Xiao Zhang, Lun-Jie Yan, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Journal of Cancer|January 3, 2022
Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapiesYu-Chuan Yan, Guang-Xiao Meng, Zi-Niu Ding, et al.
Hepatology (Baltimore, Md.)|December 24, 2019
TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic CleavageZhao-Ru Dong, Dong Sun, Ya-Fei Yang, et al.
Frontiers in Immunology|February 25, 2022
The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-AnalysisCheng-Long Han, Guang-Xiao Meng, Zi-Niu Ding, et al.
Frontiers in Oncology|March 8, 2021
Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-AnalysisKai-Xuan Liu, Jian-Guo Hong, Rui Wu, et al.
Cell Death Discovery|March 7, 2025
Thyroid hormones inhibit tumor progression and enhance the antitumor activity of lenvatinib in hepatocellular carcinoma via reprogramming glucose metabolismChun-Cheng Yang, Yu-Chuan Yan, Guo-Qiang Pan, et al.
Expert Review of Gastroenterology & Hepatology|December 8, 2022
Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysisBao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, et al.
Expert Review of Gastroenterology & Hepatology|November 6, 2023
Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysisHan Li, Hui Liu, Lun-Jie Yan, et al.
International Immunopharmacology|December 7, 2023
Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohortsJun-Yu Long, Rui-Zhe Li, Dong-Xu Wang, et al.
Cell Death & Disease|August 25, 2025
Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinomaYu-Chuan Yan, Li-Juan Shao, Guang-Xiao Meng, et al.
Journal of Cancer Research and Clinical Oncology|February 11, 2025
Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysisShi-Jia Liu, Xiao Zhang, Lun-Jie Yan, et al.
Pageof 8